News
15 days ago•3 min read
The $4.4 Billion Lie: Why Madrigal's siRNA Bet on MASH Isn't About Cures, It's About Land Grabs
Madrigal's massive siRNA licensing deal signals a dangerous consolidation in the MASH drug race. The real winner isn't the patient.
D
DailyWorld Editorial